脂肪性肝病恶化后会很复杂，最严重的是非酒精性脂肪肝炎、肝纤维化、肝硬化。非酒精性脂肪肝会导致肝功能衰竭。
Fatty liver disease can take many forms that vary in severity, with the most severe being nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. NAFLD can lead to liver failure.
脂肪性肝病恶化后会很复杂，最严重的是非酒精性脂肪肝炎、肝纤维化、肝硬化。
Fatty liver disease can take many forms that vary in severity, with the most severe being nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis.
结论肝硬化患者肝组织质量与肝血流动力学、肝纤维化指标及病理分期有关。
Conclusion liver mass in patients with liver cirrhosis is related to hepatic hemodynamics, indices for liver fibrosis and liver pathology.
目的探讨卡托普利对早期肝炎肝硬化肝纤维化指标的影响。
Objective to explore the influence of captopril on liver fibrosis index during early-stage viral liver cirrhosis.
肝硬化是肝细胞坏死后，肝纤维化和肝细胞再生所致。
Ongoing liver damage with liver cell necrosis followed by fibrosis and hepatocyte regeneration results in cirrhosis.
目的：观察二甲胶囊抗肝纤维化、治疗肝硬化(代偿期)的临床疗效和安全性。
Objective: To observe clinical effect and safety that Erjia capsule treated cirrhosis of liver.
结果：在肝炎向肝硬化转变的过程中，每一个时期均可见到肝纤维化四项指标中的一项或几项的升高。
Result: During the change of hepatitis to cirrhosis, we can discover one or more of the four indexes rise in every phase.
目的：观察不同方法治疗肝硬化前后肝血流动力学及肝纤维化指标的变化。
Objictive: To observe the change of liver blood flow and fiber index by different treatment methods in patients with liver cirrhosis.
方法采用速率法和放射免疫法(RIA)测定了81例肝硬化患者、对照组30例血清che活性和肝纤维化标志物ha水平。
Methods Adoption velocity method with RIA method measurement 81 example cirrhosis get, matched control 30 example serum che activity with cirrhosis marking thing HA level.
这种情况可能导致肝炎，肝纤维化，肝硬化和肝功能衰竭。
The condition can lead to hepatitis, fibrosis, cirrhosis and liver failure.
该病导致显著的胆汁淤积和肝内胆管增生、纤维化、肝硬化。
This leads to marked cholestasis with intrahepatic bile duct proliferation, fibrosis, and cirrhosis.
目的研究肝星状细胞(HSC)与肝纤维化和肝硬化的关系。
Objective To investigate the relationship between hepatic fibrosis and hepatic stellate cell (HSC).
科学家们在美国田纳西州的导致肝硬化疾病报告上称：一种基因“沉默”或关闭技术可能作为治疗肝纤维化潜在的新的方法。
A technique that "silences," or turns off, genes shows promise as a potential new treatment for liver fibrosis - the disease that leads to cirrhosis - scientists in Tennessee are reporting.
而癌周肝组织无论是肝硬化或肝纤维化均显示正常肝细胞的酶活性。
The surrounding liver tissue either in cirrhosis or in hepatic fibrosis appeared normal hepatic enzymatic activity.
轻度疾病的患者，与那些进展到肝纤维化或者肝硬化的患者相比，一直都有较好的反应，这显示，ALT并不能预测治疗的反应。
Patients with mild disease have better sustained responses than do those with progression to fibrosis or cirrhosis, suggesting that ALT does not predict treatment response.
非乙醇性脂肪性肝病（NAFLD）是一种常见的慢性肝病，其疾病谱包括单纯性脂肪肝、非乙醇性脂肪性肝炎（NASH）、肝纤维化及肝硬化。
Nonalcoholic fatty liver disease(NAFLD) is a kind of chronic liver disease, whose spectrum of the disease includes simple hepar adiposum, steatohepatitis(NASH), hepatic fibrosis, and cirrhosis.
《国际肝病》：如何防止肝纤维化和肝硬化？
"Hepatology Digest" : How do you prevent the progression of liver fibrosis and cirrhosis?
免疫耐受期患者只有很轻或没有肝纤维化进展，而免疫清除期是肝硬化的高发时期。
Immune-tolerant phase patients only very light or no liver fibrosis progression, and immune clearance period is liver cirrhosis of high-risk period.
有关CTGF的进一步研究将对于揭示肝纤维化及肝硬化发病和治疗机理以及临床诊治等具有重要的意义。
The further study of CTGF is important for the pathogenesis, therapeutic mechanism and the clinical treatment of hepatic fibrosis and cirrhosis.
内质网应激很可能是IETM促进肝纤维化乃至肝硬化发生的重要机制。
Endoplasmic reticulum stress is a possible mechanism in the development of liver cirrhosis promoted by IETM.
各种有害因素所致的肝损伤可表现为肝坏死、脂肪肝、胆汁郁积、肝纤维化、肝硬化及肝癌等。
The liver injury being caused by various harmful factors were manifested as hepatic necrosis, fatty liver, cholestasis, liver fibrosis, liver cirrhosis and liver cancer and so on.
酒精性肝硬化。慢性酒精性肝病使肝纤维化同时伴有肝细胞的结节状再生。
The liver injury with chronic alcoholism leads to fibrosis and regeneration of the hepatocytes in nodules.
结论血清四项可作为判断肝纤维化及肝硬化的较好的指标。
Conclusions Detection of LN CIV PIIIP and HA in diagnosing LC and LF have made considerable clinical value.
它们可反映慢性肝炎患儿肝纤维化的严重程度。 因此，对慢性肝炎和早期肝硬化的诊断有临床应用价值。
The values of the 4 markers may reflect the severity of chronic hepatitis in children, and may have potential applicability in clinical diagnosis of chronic hepatitis and early cirrhosis.
目的研究中药制剂达美施乙肝三号治疗乙肝后肝纤维化、肝硬化的治疗效果及安全性。
Objective To evaluate the efficiency and safety of "TINMAX" HB-3 Herbal Compound (cpd) in treatment of hepatofibrosis and cirrhosis post chronic hepatitis B.
目的研究中药制剂达美施乙肝三号治疗乙肝后肝纤维化、肝硬化的治疗效果及安全性。
Objective To evaluate the efficiency and safety of "TINMAX" HB-3 Herbal Compound (cpd) in treatment of hepatofibrosis and cirrhosis post chronic hepatitis B.
应用推荐